Half-lives of IL-15 agonists in mice
| IL-15 agonist | Route of administration* | Mouse t1/2 hour | Reference |
| MS~IL-15 | Subcutaneous | 168 (30†) | This work |
| MSGDM~IL-15 | Subcutaneous | 50 | This work |
| IL-15 | Intravenous | 0.64 | 30 |
| IL-15 | Intraperitoneal | 0.50 | 31 |
| RLI (IL-15-IL-15Rαsushi) | Intraperitoneal | 3 | 35 |
| hetIL-15 (IL-15/IL-15Rα) | Intraperitoneal | 4 | 53 |
| ALT-803 (IL-15 N72D/IL-15Rα-Fc) | Intravenous and subcutaneous | 7.5 | 54 |
| NKTR-255 (PEG-IL-15) | Intravenous | 14 | 32 |
*Not all routes of administration have been reported in mice.
†Second phase of C versus t plot.
IL, interleukin; MS, microspheres.